Date: 2014-10-28
Type of information: Collaboration agreement
Compound: marizomib, bevacizumab
Company: Triphase Accelerator (Canada - USA - CA) Celgene (USA - NJ)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism: proteasome inhibitor/monoclonal antibody. Marizomib is a novel proteasome inhibitor that irreversibly targets and inhibits all three proteasome subunits, allowing for more durable and sustained responses. Bevacizumab is an antibody that specifically binds and blocks the biological effects of VEGF (vascular endothelial growth factor), the key driver of tumor angiogenesis.
Disease: glioblastoma
Details: * On October 28, 2014, Triphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, announced an expansion of its strategic collaboration with Celgene Corporation. The
supplemental agreement adds a Phase I development program that will explore combining an intravenous (IV) formulation of marizomib with bevacizumab in glioblastoma. Triphase is developing marizomib in both intravenous (IV) and oral formulations as a potential best-in-class proteasome inhibitor for hematologic malignancies and solid tumors. Marizomib has demonstrated activity in a Phase I study in patients with multiple myeloma refractory to lenalidomide or bortezomib. An IV formulation has been evaluated in more than 230 patients in four Phase I studies in patients with solid and hematologic malignancies, either as a single agent or in combination with dexamethasone or an HDAC inhibitor. Triphase is currently evaluating the IV formulation in an ongoing Phase II clinical trial in combination with dexamethasone in a highly refractory multiple myeloma population, including those refractory to carfilzomib. It is also being tested in a Phase I study in combination with pomalidomide and dexamethasone in relapsed and refractory multiple myeloma. Triphase is also evaluating an oral formulation of marizomib in IND-enabling studies.
Financial terms: Under the supplemental agreement, Triphase will receive additional development funds through a cost sharing arrangement with Celgene. Triphase will control product development and retain all commercial rights to marizomib until and unless Celgene exercises its option to acquire the product from Triphase for an undisclosed payment, at which time Triphase would then be eligible to receive regulatory and sales milestone payments.
Latest news:
